Compare PFX & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFX | PYPD |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.5M | 81.7M |
| IPO Year | N/A | 2014 |
| Metric | PFX | PYPD |
|---|---|---|
| Price | $41.01 | $4.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 650.0 | ★ 57.2K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.30 | $2.44 |
| 52 Week High | $53.59 | $5.12 |
| Indicator | PFX | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 63.46 |
| Support Level | $39.16 | $4.03 |
| Resistance Level | $44.56 | $5.05 |
| Average True Range (ATR) | 0.93 | 0.18 |
| MACD | 0.20 | 0.05 |
| Stochastic Oscillator | 63.80 | 91.45 |
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.